WFIKKN1 (WAP, Follistatin/Kazal, Immunoglobulin, Kunitz, and Netrin domain-containing protein 1), also known as GASP-2 (Growth and Differentiation Factor-associated Serum Protein-2), is a major endogenous regulator of the TGF-beta superfamily. By specifically binding and inhibiting myostatin (GDF8) and GDF11, WFIKKN1 plays a pivotal role in muscle mass regulation, metabolic homeostasis, and joint preservation. As the therapeutic focus shifts toward highly selective muscle-growth promoters and anti-atrophy treatments, WFIKKN1 has emerged as a critical target and scaffold for engineering next-generation biologics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for WFIKKN1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | WFIKKN1 Recombinant Protein (Full-Length / Domain-Specific) High purity (>95%), Endotoxin controlled (<1 EU/ug). Sequence Verified. HEK293 expressed for native glycosylation. |
View WFIKKN1 Products |
| Gene Delivery | WFIKKN1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View WFIKKN1 Products |
| Benchmark Ab | Anti-WFIKKN1 Recombinant Antibody High-affinity positive control for ELISA, SPR, and Western Blot. |
View WFIKKN1 Products |
| Validator | WFIKKN1 siRNA Set Target-specific knockdown verification in muscle and osteoblast cell lines. |
View WFIKKN1 Products |
| Related Target A | GDF8 (Myostatin) Primary ligand inhibited by WFIKKN1; key target for muscle wasting diseases. |
View GDF8 Products |
| Related Target B | GDF11 Homologous ligand; critical for off-target selectivity and safety profiling. |
View GDF11 Products |
| Related Target C | WFIKKN2 (GASP-1) Subfamily homolog; essential for counter-screening to ensure drug specificity. |
View WFIKKN2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GDF8 vs. GDF11 Selectivity Profiling | Human, mouse, and cynomolgus ortholog proteins available with >95% purity for precise cross-reactivity testing. |
| Subfamily Homolog Cross-Reactivity | WFIKKN1 and WFIKKN2 panel proteins strictly verified by mass spectrometry and theoretical MW comparison. |
| Lack of Controls | Clinical benchmark antibodies and sequence-verified positive controls included. |
| False Positives in Binding Assays | Validated siRNA sets included for functional knockdown and specificity verification. |
Live WFIKKN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for WFIKKN1-associated therapeutics is intensifying as the industry seeks to overcome the limitations of first-generation myostatin inhibitors. While early clinical attempts targeting GDF8 directly faced challenges due to off-target cross-reactivity with GDF11 (which shares 90% sequence identity), targeting the endogenous regulator WFIKKN1 or utilizing its specific domains offers a highly nuanced approach. The next wave of R&D is focused on engineering domain-specific WFIKKN1 fusion proteins and monoclonal antibodies that selectively block GDF8 while sparing GDF11, minimizing systemic side effects in sarcopenia, cachexia, and muscular dystrophies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Fusion Proteins | Biopharma Innovators | Sarcopenia, Muscle Atrophy | Binding Affinity Assay (Need HEK293-expressed WFIKKN1 to preserve native glycosylation and folding) |
| Monoclonal Antibodies | Academic & Clinical Consortia | Muscular Dystrophy, Osteoarthritis | Epitope Mapping & Blockade (Need high-purity WFIKKN1 domain-specific fragments) |
| Gene Therapy (AAV/mRNA) | Preclinical Startups | FSHD, Rare Muscle Diseases | Expression Validation (Need Lentivirus for stable cell line construction and FACS validation) |